Posted by Michael Wonder on 23 Dec 2024
Over 1,000 people with advanced breast cancer set to benefit from new once a day tablet
19 December 2024 - We’ve issued final draft guidance recommending a new once a day tablet that is set to benefit around 1,100 people with a type of advanced breast cancer.
Our final draft guidance recommends elacestrant (Korserdu, Menarini Stemline) for treating oestrogen receptor positive, HER2 negative, locally advanced or metastatic breast cancer with an activating ESR1 mutation.
